Figures computed from official regulatory filings — .
Analysttarget 5.5 USD (+493%) · consensus 4.43/5 · 6 buy · 1 hold · 0 sell
Ownershipinsiders 4.86% · institutions 48.22% · short 19.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Lineage Cell Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
121 buys104 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Amin Dipti | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BRADSHER NEAL Ctrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ANDREWS DEBORAH Jtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Russell Angus C.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mulroy Michael H.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jayasuriya Anula | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Culley Brian Mtrack record | Buy | $24.5K | conv 60Unusual sizeFirst in 12mo | SEC |
| Howe Jill Ann | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Samuel George A. III | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Culley Brian Mtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Samuel George A. III | Other | $4.5K | SEC |
| Culley Brian Mtrack record | Other | $23.2K | SEC |
| Culley Brian Mtrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Samuel George A. III | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Culley Brian Mtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Samuel George A. III | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kim Tonytrack record | AwardD (derivative) | $229.8K | SEC |
| Menge Steven Reid | AwardD (derivative) | $32.5K | SEC |
| Fairbairn Robert Wtrack record | Sell | $4.7 | SEC |
| Fairbairn Robert Wtrack record | Sell | $143K | SEC |
| Samuel George A. III | Other | $109.2 | Unusual size | SEC |
| Culley Brian Mtrack record | Other | $561.1 | SEC |
| Culley Brian Mtrack record | Award | n/a (No price was disclosed in the filing) | SEC |
| Samuel George A. III | Award | n/a (No price was disclosed in the filing) | SEC |
| Saba Capital Management, L.P.track record | Other | $454.5M | Unusual size | SEC |